Australian Doctor 14th June Issue | Page 21

HOW TO TREAT 21
ausdoc . com . au 14 JUNE 2024

HOW TO TREAT 21

Box 3 . Eosinophilic oesophagitis endoscopic reference score ( EREFS score )
• Oedema ( loss of vascular markings ): — Grade 0 : Distinct vascularity . — Grade 1 : Absent or decreased .
• Rings ( trachealisation , see figure 3 ): — Grade 0 : None . — Grade 1 : Mild ( ridges ). — Grade 2 : Moderate ( distinct rings ). — Grade 3 : Severe ( scope will not pass ).
Samir / CC BY : bit . ly : 3QOQEGN
performed at about 8-12 weeks after starting treatment to assess response . Second-line therapy is discussed and implemented if there is no response to initial therapy . This is again determined by evaluating the advantages and disadvantages of each treatment and collaborating with the patient in order to formulate a treatment approach .
The duration of therapy for each management approach is not well defined ; however , multiple studies have demonstrated that maintenance therapy is necessary because of a high relapse rate . A 2020 study evaluating maintenance therapy with BOTs reported disease relapse
• Exudate ( white plaques ): — Grade 0 : None . — Grade 1 : Mild . — Grade 2 : Severe .
• Furrows ( vertical lines ): — Grade 0 : None . — Grade 1 : Mild . — Grade 2 : Severe .
at a median of 87 days in their placebo group
37 , 38
.
PPI therapy
PPI therapy is thought to improve
EoE via both acid blockade and direct anti-inflammatory effects , including decreasing the production of IL-13-induced eotaxin-3 . 40
• Stricture : — Grade 0 : Absent . — Grade 1 : Present .
Eotaxin-3 is a chemoattractant and thereby lures eosinophils into the oesophagus in EoE . 41 A high-dose PPI — for example , 40mg pantopra-
Adapted from Hirano et al 2013 26
Figure 3 . Ringed oesophagus .
zole bd — is recommended . 42 This approach leads to histological remission
in 50.5 % of patients and symp-
Box 4 . Diagnostic criteria for eosinophilic oesophagitis
• Symptoms of oesophageal dysfunction ( dysphagia , food bolus impaction , heartburn , noncardiac chest pain .
• Endoscopic biopsies demonstrating histological features of 15 or more eosinophils / high-powered field .
• Alternative causes of oesophageal dysfunction with eosinophilia excluded ( eg , achalasia , infection , connective tissue disorder , hypereosinophilic syndrome , coeliac disease , inflammatory bowel disease and medication-related oesophagitis ).
Note : All three criteria are needed to make a diagnosis . Source : Dellon ES et al 2018 31
Box 5 . Diseases associated with oesophageal eosinophilia
• Gastro-oesophageal reflux disease ( see figures 6 and 7 ).
• Eosinophilic oesophagitis .
• Eosinophilic gastroenteritis .
• Coeliac disease .
• Crohn ’ s disease .
• Infection ( fungal , viral or parasitic ).
• Drug-induced eosinophilic oesophagitis .
• Achalasia ( see figure 8 ).
• Hypereosinophilic syndrome .
• Vasculitis .
• Connective tissue disease .
• Graft-versus-host disease .
Figure 4 . Histopathology of eosinophilic oesophagitis , showing multiple intraepithelial eosinophils and oedema seen as white clearings . H & E stain .
JVinocur / CC BY / bit . ly / 3SwgySi Mikael Häggström , M . D / CC BY : bit . ly / 3QMYXEg
tomatic improvement in 60.8-71 %. 42 PPI therapy improves fibrous remodelling in patients with EoE . 43 Further benefit was not found with treatment of longer than 12 weeks , with no significant difference between the different PPI drugs when used at equivalent doses . 44 In patients who responded to PPI therapy , a reduced dose was effective in maintaining histological remission in 69.2 %. 44
Patients with a stricturing phenotype ( rings and / or strictures ) have a significantly reduced response ( by approximately 50 %) to PPI therapy compared with those who have an inflammatory phenotype . 44
Dietary therapy
Historically , the dietary approach
to EoE consisted of elimination of the six most common food allergens — including dairy , gluten , egg , soy , nuts , fish and seafood — for 6-8 weeks . This was termed the sixfood elimination diet ( 6-FED ) and achieved histological remission in 70 % of patients . 2 To detect the specific food trigger , sequential reintroduction of the food group is initiated followed by endoscopy , with biopsy performed after each reintroduction . This process is challenging for many patients given the numerous appointments and repeat endoscopies required .
Comparing the 6-FED and 4-FED ( this eliminates dairy , soy , egg and wheat ), it emerged that dairy and gluten were the most common culprits
for triggering EoE in patients .
Subsequently , the 2-FED was
helpful but is not required for the
designed . This approach restricted
diagnosis . 35
dairy and gluten in patients and
MANAGEMENT
PROMPT , targeted therapy is imper-
demonstrated a 43 % symptomatic and histological remission . 44A Non-responders were subsequently
ative in managing EoE successfully to prevent both symptoms and progression to fibrostenotic disease .
Figure 5 . Barium swallow showing features of eosinophilic oesophagitis .
offered a 4-FED for six weeks , and if there was no response , a 6-FED was then commenced , with remission
Progression to fibrosis has been
rates of 60 % and 79 %, respectively .
demonstrated in 57-90 % of patients
20 years ). 36 In addition , patients also
topical corticosteroids ( STC )/ budes-
with all management options dis-
This step-up approach enabled a 20 %
with EoE . 29 This increases with the
demonstrate increased development
onide orodispersible tablet ( BOT )
cussed at time of diagnosis to ensure
decrease in endoscopic procedures
duration of delay in the diagnosis :
of strictures with a delay in diagnosis .
therapy , dietary therapy and endo-
adherence is maximised ( see fig-
as well as less time on a restrictive
46.5 % ( diagnostic delay 0-2 years ) to
Current treatment recommen-
scopic therapy . The treatment
ure 9 ). Depending on the approach ,
diet . 44A The efficacy of long-term die-
87.5 % ( diagnostic delay longer than
dations include : PPIs , swallowed
approach is targeted to the patient ,
an endoscopy with biopsies is
tary therapy is poor , with
PAGE 24